Yuri Teranishi-Ikawa

Company: Chugai Pharmaceuticals

Job title: Principal Scientist

Seminars:

Delving into Chugai Pharmaceutical’s Multidimensional Optimization Process to Improve Both the Therapeutic Potential & the Manufacturability 4:00 pm

Exploring FAST-Ig™, designed for efficient production of bispecific antibodies and ACTFc®, to improve antibody pharmacokinetics Applying these unique technology platforms to NXT007, a next-generation version of emicizumab for hemophilia A Discussing future directions for creating novel bispecific antibodies and beyondRead more

day: Day One